{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-036769","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.651237+00:00","generated_at":"2026-06-22T07:03:33.748910+00:00","sec_items":["1.01","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Aptevo extends shareholder rights plan expiration to November 4, 2023","bullets":["Amendment No. 2 to Rights Agreement extends Final Expiration Date to Nov 4, 2023.","Rights Agreement originally dated Nov 8, 2020, amended Nov 5, 2021, and now Nov 4, 2022.","Rights pertain to contingent purchase of one one-thousandth of Series A Junior Participating Preferred Stock.","Broadridge Corporate Issuer Solutions remains Rights Agent.","No changes to other terms or exercise price of rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-036769","json":"https://secwatch.observer/filing/0001564590-22-036769.json","markdown":"https://secwatch.observer/filing/0001564590-22-036769.md","text":"https://secwatch.observer/filing/0001564590-22-036769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000156459022036769/0001564590-22-036769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000156459022036769/apvo-8k_20221104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:03:33.748910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc05ce34109a3d534ffebe487ec3e299ddbb339d","claim":"Aptevo Therapeutics Inc. amended \"Rights Agreement\" with Broadridge Corporate Issuer Solutions, Inc. valued at 1011 (effective 2022-11-04).","evidence_excerpt":"On November 4, 2022, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended on November 5, 2021 (the “Rights Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000156459022036769/0001564590-22-036769-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Broadridge Corporate Issuer Solutions, Inc."},{"label":"Value","value":"1011"},{"label":"Effective","value":"2022-11-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}